Immunological Dynamics in Glioma Microenvironments

Gliomas reside within a uniquely immunosuppressive niche shaped by the central nervous system’s specialised barriers and the tumour’s active modulation of local immunity. Resident microglia and infiltrating macrophages adopt a spectrum of activation states, often skewed towards a pro-tumour phenotype that secretes anti-inflammatory cytokines and supports angiogenesis. Myeloid-derived suppressor cells and regulatory T cells accumulate, further dampening cytotoxic T-cell responses through nutrient depletion, checkpoint ligand expression and immunosuppressive cytokine release. Hypoxic regions amplify these effects by stabilising HIF-1α and upregulating inhibitory factors. Conversely, antigen-presenting cells such as dendritic cells and monocyte-derived macrophages may be harnessed to present tumour neoantigens, yet their function is frequently impaired by metabolic competition and inhibitory signals within the microenvironment. Together, these elements establish a dynamic equilibrium in which glioma cells evade immune surveillance, adaptively reshape immune cell composition and resist conventional and immune-based therapies. Advances in understanding the interplay among tumour cells, stromal components and infiltrating leukocytes are now guiding the design of combinatorial strategies to restore effective anti-tumour immunity.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Immunological Dynamics in Glioma Microenvironments publication trend

The graph below shows the total number of articles in immunological dynamics in glioma microenvironments across all publications each year (not limited to Nature Index journals).

Technical terms

Regulatory T cells (Tregs): A subset of CD4+ T lymphocytes that suppress immune responses and maintain tolerance, often co-opted by tumours to inhibit anti-tumour immunity.

Myeloid-derived suppressor cells (MDSCs): Heterogeneous population of immature myeloid cells that inhibit T-cell activation through nutrient depletion, reactive oxygen species and cytokine production.

Antigen-presenting cells (APCs): Immune cells such as dendritic cells, macrophages and B cells that process and present peptide antigens to T cells via major histocompatibility complex molecules.

Tumour-associated macrophages (TAMs): Macrophages residing within tumours that often exhibit an immunosuppressive, tissue-reparative phenotype supporting tumour growth and vascularisation.

Blood–brain barrier (BBB): A selective endothelial interface that restricts access of cells and molecules to the central nervous system, influencing drug delivery and immune cell infiltration.

Immune checkpoint: Regulatory pathway (e.g., PD-1/PD-L1, CTLA-4) that maintains self-tolerance and modulates the amplitude of immune responses, frequently exploited by tumours to evade detection.

References

1. Next-generation antigen-presenting cell immune therapeutics for gliomas. Journal of Clinical Investigation (2023).
2. Complement factor H is an ICOS ligand modulating Tregs in the glioma microenvironment. Cancer Immunology Research (2024).
3. Combination of tumor antigen drainage and immune activation to promote a cancer-immunity cycle against glioblastoma. Cellular and Molecular Life Sciences (2024).
4. Hypoxia Potentiates Glioma-Mediated Immunosuppression. PLOS ONE (2011).